Connect with us

Politics

GILD Stock: Gilead Posts Its Best Growth In 7 Years As Cancer Drug Sales Rocket

Published

on

Gilead Sciences (GILD) crushed fourth-quarter expectations Thursday and issued an unexpectedly bullish outlook that buoyed GILD stock.




X



The company hasn’t seen growth this strong since 2015 at the heyday of Gilead’s hepatitis C drug franchise, Chief Executive Daniel O’Day said on a call with reporters. In 2022, total product sales grew 8%, excluding the impact of Covid treatment Veklury.

Advertisement

The lion’s share of growth last year came from Gilead’s HIV treatments and oncology medicines. Revenue from Biktarvy, an HIV drug, surged 20% and topped $10 billion for the first time. Sales of cancer treatments crossed the $2 billion mark, rocketing 71%.

As a result, Gilead guided to 4%-6% growth in its base business. Analysts had forecast a decline.

“Today, our growth is driven by a far more diverse portfolio, including our therapies for HIV and oncology,” he said. “When we laid out our transformation strategy in 2019, this was our aim: To return to growth and to ensure growth would be sustainable.”

In after-hours trading on today’s stock market, GILD stock jumped 2.4% near 83.40. Shares lost 3.1% during the regular session and closed at 81.39.

Advertisement

GILD Stock: Earnings Skyrocket

During the December quarter, adjusted Gilead earnings launched 142% higher to $1.67 a share, beating expectations for $1.51, according to FactSet. Sales inched 2% higher to $7.33 billion — well above Wall Street’s estimate for $6.63 billion.

Sales of Covid treatment Veklury plunged 26% to $1 billion, driven by lower hospitalization rates. But CEO Day sees room for Veklury to maintain a role in Covid treatment as the virus becomes an endemic threat. To date, more than 12 million people around the world have received Veklury.

“Veklury continues to play a role in addressing the public health challenges of the pandemic,” he said.

Excluding Veklury’s impact, Gilead’s total fourth-quarter product sales climbed 9% to $6.3 billion.

Advertisement

The company’s cancer treatments also tacked on another quarter of bullish growth and narrowly beat expectations. Sales of cell therapies Yescarta and Tecartus soared a collective 75% to $419 million. Analysts had called for a total $414 million from the duo.

Meanwhile, Gilead’s breast cancer medicine, Trodelvy, brought in $195 million in sales, growing 65%, but missing forecasts for $197 million.

Sales of HIV treatments also jumped 5% to $4.8 billion — helped by 15% growth from Biktarvy to $2.9 billion. That was narrowly above GILD stock analysts’ call for $2.83 billion.

Guidance Above Forecasts

For the year, Gilead expects $26 billion to $26.5 billion in sales, including roughly $2 billion from Veklury. Analysts had actually called for decline in product sales to $25.67 billion. They had also projected just $1.38 billion from Veklury.

Advertisement

Gilead stock recently fell below the low end of a flat base with a buy point at 89.84, according to MarketSmith.com.

Shares have a strong IBD Digital Relative Strength Rating of 90. This puts GILD stock in the leading 10% of all stocks in terms of 12-month performance.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

Advertisement

Here’s What’s Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

Eli Lilly Dives After A ‘Bump In The Road’ Shakes Its Newest Diabetes Drug

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Follow Premarket And After-The-Open Action With IBD Experts

Advertisement

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Source link

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *